Hi John,
The PT was written wrong....So it just so happens you were by chance correct ! Quite honestly, and i say this without expressing any disappointment....Or personal feeling toward the Analysis, and it has nothing to do with NOT agreeing with his assessment...Although i do not.
This IMO has every to do with management not better informing investors and analysis. As i mentioned previously, Graig S of Jeffries is under the impression Gvax is in "very early stage trial P1" Therefore there is nothing in his price "model" to reflect its Value. Gvax has several "Late stage" P2 trials for Gvax ongoing @ JHU...........Yes it is also used in Combo with other drugs in Phase 1b...Gvax for Panc is going into a P3, [no news release]
The trial design has yet to start....Zero consideration for a "proven safety" of Libi The Analysis own opinion is that it will most likely be approved. [ LIBI] In the absence of clarification from BPAX with FDA as to the particulars of new trial....Any positive news.....Will surely help ! I am sure the lawsuits are contributing to the silence....
Not sure where the 2016 estimated completion date comes from !
JMHO
GLTA
News 
Market Data 
Discover 
